GlaxoSmithKline Pharmaceuticals has a current ratio of 2.03. It generally indicates good short-term financial strength.
The historical rank and industry rank for GlaxoSmithKline Pharmaceuticals's Current Ratio or its related term are showing as below:
NSE:GLAXO'
s Current Ratio Range Over the Past 10 Years
Min: 1.36 Med: 1.82 Max: 2.32
Current: 2.03
During the past 13 years, GlaxoSmithKline Pharmaceuticals's highest Current Ratio was 2.32. The lowest was 1.36. And the median was 1.82.
NSE:GLAXO's Current Ratio is ranked better than 51.46% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs NSE:GLAXO: 2.03
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
GlaxoSmithKline Pharmaceuticals Current Ratio Related Terms
GlaxoSmithKline Pharmaceuticals Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pharmaceuticals Current Ratio Chart
NSE:GLAXO vs LLY, JNJ, ABBV: Current Ratio Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a Current Ratio of 2.03 as of Mar. 2026. This is 12% above median its historical median of 1.82. Over the past decade, GlaxoSmithKline Pharmaceuticals' Current Ratio has ranged from 1.36 to 2.32. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #483 out of 995 companies in the Drug Manufacturers industry, placing it in the top 48.5%.
Is GlaxoSmithKline Pharmaceuticals' Current Ratio too high?
GlaxoSmithKline Pharmaceuticals' current Current Ratio of 2.03 is 12% above median its 10-year median of 1.82. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 2.32. The Drug Manufacturers industry median Current Ratio is 2.00. GlaxoSmithKline Pharmaceuticals' value of 2.03 is 1.5% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #483 out of 995 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' Current Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #483 out of 995 companies for Current Ratio. This puts GlaxoSmithKline Pharmaceuticals in the upper half of its industry. The industry median Current Ratio is 2.00. GlaxoSmithKline Pharmaceuticals' value of 2.03 is 1.5% above this benchmark. Historically, GlaxoSmithKline Pharmaceuticals' own Current Ratio has ranged from 1.36 to 2.32 over the past decade. While the company's 10-year median is 1.82 vs. the industry median of 2.00, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current Current Ratio of 2.03 is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current Current Ratio is 2.03, which is 12% above median its own 10-year median of 1.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,610.20, compared to a current price of ₹2,354.80 — trading 9.8% below its estimated fair value. The current Current Ratio is 2.03, which is 12% above median its 10-year median of 1.82 and 1.5% above the Drug Manufacturers industry median of 2.00. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current Current Ratio is 2.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹2,354.80 is trading 9.8% below its estimated GF Value™ of ₹2,610.20.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:GLAXO:
Current Ratio: 2.03 (12% above median its 10-year median of 1.82)
GF Value™: ₹2,610.20 vs. price of ₹2,354.80 (9.8% below fair value)
Industry Position: 1.5% above the Drug Manufacturers median (#483 of 995)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Business Description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
73GF Score
Get the complete analysis for NSE:GLAXO
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
